

Gene Therapy and The Cure To Cancer: Triggering B-Cell and T-cell White Blood Cell Antibody Production

Alan Peter Garfoot Jnr. Dip. H.E. Cert. H.E.

Independent Scientist & Concept Designer, England.

Abstract

Recent advancements in gene therapy, where synthetically engineered artificial viruses impregnate target cell types with DNA specifically designed to trigger alterations and adaptations in cell function and morphology, these are currently redefining how we see the future of the treatment of cancer. Through introducing a novel and original innovative strategy to effectively trigger a select portion of the whole immune system, the white blood cells producing antibodies, into successfully producing the optimum of tumor eliminating antibodies. This theoretical research paper explores the hypothetical treatment highlighting the core mechanisms of action for gene therapy cancer treatment wherein synthetically modified gene-sequences are incorporated to trigger immune system changes. Lymphocyte white blood cells specifically, all being triggered through the synthetic cells to produce cancer targeting and destroying antibodies, without compromising the overall immunological ability of the body to combat latently occurring infections; as the pathogen consuming neutrophils would be unaffected. A portion of the immune system is thus reprogrammed through the gene therapy process to specifically target and eliminate cancerous tumors in the body. This study delves explicitly into the specific biochemical mechanisms of action, therapeutic methods, and potential recovery outcomes of this form of gene therapy treatment based on a cross-referenced data metanalysis.

INTRODUCTION

The integration of white blood cell targeted gene therapy into current methods of cancer treatment represents a significant paradigm shift, through enabling the genetic manipulation of lymphocyte cellular functions through the synthetic introduction of specific genes in order for these cells to target cancerous tumor malignancies through their antibody production with a continuous effect precision tuned to the cancer type. This report examines a novel proposition where gene therapy induces WBCs to produce tumor-specific antigens, thereby triggering a systematic immunological reaction to cancerous tumors while still preserving the bodies innate ability to fight acquired infections. We will explore the underlying biochemical causations, mechanisms of action, and potential for future research into therapeutic benefits of this form of gene therapy.

THEORETICAL BACKGROUND

Gene therapy for cancer immunotherapy involves modifying WBCs, specifically T-cells and B-cells, to express tumor-associated antigens (TAAs) while maintaining their

pathogen-fighting capabilities. The primary biochemical pathway begins with the use of viral vectors, often lentiviruses or adenoviruses, to deliver genes encoding TAAs into WBCs. These antigens are subsequently processed and presented on the cell surface via major histocompatibility complex (MHC) molecules.

The introduction of TAAs into WBCs activates both the adaptive and innate immune responses. In this context, the therapy strategically avoids involving phagocytic cells, such as macrophages and neutrophils, which are primarily responsible for engulfing pathogens. This selective targeting ensures that the patient's immune system retains its capacity to fend off infections while undergoing cancer treatment.

***Corresponding Author:** Alan Peter Garfoot Jnr. Dip. H.E. Cert. H.E. Independent Scientist & Concept Designer, England.

CONCEPTUAL ANALYSIS

Upon presentation of TAAs on WBCs, CD8+ cytotoxic T-cells recognize these antigens through their T-cell receptors (TCRs). This recognition event initiates a signaling cascade involving the activation of the nuclear factor of activated T-cells (NFAT) pathway, leading to the transcription of genes essential for T-cell proliferation and differentiation. Additionally, co-stimulatory signals provided by antigen-presenting cells (APCs) enhance this response, resulting in the expansion of tumor-specific T-cells.

The immune response is further amplified through the secretion of cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN- γ), which enhance T-cell cytotoxicity and promote the recruitment of other immune cells to the tumor microenvironment. Importantly, the inclusion of memory T-cells in the response ensures long-term immunity, reducing the likelihood of cancer recurrence.

This gene therapy approach is designed to counteract the immunosuppressive effects typically exerted by the tumor microenvironment (TME). Tumors often exploit immune checkpoint pathways, such as PD-1/PD-L1, to evade immune surveillance. By modifying WBCs to express TAAs and enhancing their activation, this therapy effectively bypasses these suppressive mechanisms, enabling a potent and sustained anti-tumor response.

The therapeutic goal of this gene therapy approach is to achieve complete tumor eradication by mobilizing the entire immune system against cancer cells. In preclinical and early clinical studies, the induction of a robust immune response through gene therapy has led to significant tumor regression in various cancer types, including lung and brain cancers (Rafiq et al., 2020).

DISCUSSION

The revolutionary technique of using gene therapy to trigger WBCs to produce antigens represents a cutting-edge approach in cancer immunotherapy. By focusing on antigens specific to the tumor, this strategy minimizes collateral damage to healthy tissues and preserves the immune system's ability to combat infections. The selective activation of T-cells, coupled with the inhibition of immune checkpoint pathways, creates a potent anti-tumor environment that is difficult for cancer cells to escape.

However, the success of this therapy is contingent on several factors, including the efficiency of gene delivery, the persistence of antigen expression, and the management of potential immune-related adverse events. Future research should focus on optimizing vector

design, improving the specificity of antigen targeting, and developing strategies to modulate the immune response to prevent autoimmunity.

CONCLUSION

Gene therapy-induced antigen production in WBCs offers a promising avenue for cancer treatment, particularly for tumors like lung and brain cancers. By selectively triggering a specific portion of the body's immune system, this radical new treatment has the capacity to achieve effective tumor destruction within a relatively brief period, although recovery times will vary based on cancer stage. The pursuit of further research into the area and pioneering clinical trials will pave the way for this therapy, ensuring its safety, efficacy, and broad applicability to all cancer types.

BIBLIOGRAPHY

1. Brown, C.E., Alizadeh, D., Starr, R., Weng, L., Wagner, J.R., Naranjo, A., Ostberg, J.R., Badie, B., Jensen, M.C. (2016) 'Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.' *New England Journal of Medicine*, 375, 2561-2569. DOI: 10.1056/NEJMoa1610497.
2. Choi, B.D., Maus, M.V., June, C.H., Sampson, J.H. (2019) 'Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.' *Clinical Cancer Research*, 25(7), 2042-2048. DOI: 10.1158/1078-0432.CCR-18-2534.
3. Farkona, S., Diamandis, E.P., Blasutig, I.M. (2016) 'Cancer immunotherapy: the beginning of the end of cancer?' *BMC Medicine*, 14, 73. DOI: 10.1186/s12916-016-0623-5.
4. June, C.H., O'Connor, R.S., Kawalekar, O.U., Ghassemi, S., Milone, M.C. (2018) 'CAR T cell immunotherapy for human cancer.' *Science*, 359(6382), 1361-1365. DOI: 10.1126/science.aar6711.
5. Marofi, F., Motavalli, R., Safonov, V.A., Thangavelu, L., Yumashev, A.V., Alexander, M., Shomali, N., Chartrand, M.S., Pathak, Y. (2021) 'CAR T cells in solid tumors: challenges and opportunities.' *Stem Cell Research & Therapy*, 12, 81. DOI: 10.1186/s13287-020-02114-5.
6. Rafiq, S., Hackett, C.S., Brentjens, R.J. (2020) 'Engineering strategies to overcome the current roadblocks in CAR T cell therapy.' *Nature Reviews Clinical Oncology*, 17(3), 147-167. DOI: 10.1038/s41571-019-0297-y.
7. Ribas, A., Wolchok, J.D. (2018) 'Cancer immunotherapy using checkpoint blockade.' *Science*, 359(6382), 1350-1355. DOI: 10.1126/science.aar4060.

8. Rossi, J., Paczkowski, P., Shen, Y.W., Morse, K., Flynn, B., Kaiser, A., Ng, C., Gallatin, K., Cain, T., Fan, R., Breton, C.S., Duvall, M.G., Qian, D., Orentas, R., Grupp, S.A., Levine, B.L., Lam, B.K., June, C.H., Mackall, C.L., Jensen, M.C., et al. (2021) 'Preclinical studies of CAR T cell immunotherapy for lung cancer.' *Journal of Clinical Investigation*, 131(1), e138646. DOI: 10.1172/JCI138646.
9. Zhao, L., Cao, Y.J. (2019) 'Engineered T Cell Therapy for Cancer in the Clinic.' *Frontiers in Immunology*, 10, 2250. DOI: 10.3389/fimmu.2019.02250.
10. Zhou, J., Choi, B.C., Margineantu, D., Hesson, J., Lu, C., Puri, M., Gottardo, R., McIntosh, M., Hockenbery, D.M., Riddell, S.R. (2019) 'Phase I trial of autologous CD8+ T cell therapy targeting NY-ESO-1 for patients with metastatic melanoma.' *Journal of Clinical Oncology*, 37(29), 2544-2555. DOI: 10.1200/JCO.19.00609.

Cite this article: Alan Peter Garfoot Jnr. Dip. H.E. Cert. H.E. *Gene Therapy and The Cure To Cancer: Triggering B-Cell and T-cell White Blood Cell Antibody Production. International Journal of Research in Medical and Clinical Sciences.* 2025; 3(2): 01-03

Copyright: © 2025. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.